Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexion Pharmaceuticals, Inc.
This is a US observational registry of pediatric NF1 PN participants treated with selumetinib.
Age
2–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants diagnosed with NF1 and PN
Started selumetinib between the ages of 2 to 18 years inclusive, and initiated selumetinib treatment on or after 10 April 2020, including patients who:
Discontinued selumetinib before enrollment; or
Initiated treatment before enrollment and are currently on selumetinib; or
Initiated selumetinib on the day of enrollment or intend to initiate selumetinib within 3 months after enrollment
Able to give written informed consent. Participant or participant's parent/legal guardian must be willing and able to give written informed consent and the participant (if minor) must be willing to give written informed assent.
You may not be if
Participants currently participating in any clinical trials at time of enrollment or initiation of selumetinib.
